|
|
|
|
|
ニューズレター
|
Abstract
These days we all suffer from information overload. To overcome this problem,
the Respiratory Drug News service focuses specifically on respiratory
drugs, delivering the information you need in a timely, flexible and
convenient format.
The largest respiratory sector, asthma, is valued at around US$15 billion
globally. The COPD market is valued at US$4-5 billion, but is fast growing and
expected to double in the next five years. Future market growth will be driven
by increasing disease awareness, an increasing patient pool, both in the
paediatric asthma sector and the ageing population susceptible to COPD, and
the launch of newer, more expensive therapies targeting areas of high unmet
clinical need. These will be offset to some extent by the launch of new
generics and the erosion of monotherapy product sales by combination drugs.
For pharmaceutical company executives, researchers and commercial managers,
this sector is taking an important role in the industry' s plans; staying in
touch with the latest twists and turns, however, is another matter. That is
why this new, daily-updated online information service is essential.
Respiratory Drugs News provides:
- The full text of the latest news reported on all types of respiratory
drugs and their development
- An easy-to-use interface that immediately takes you to the most recently
updated information
- An extensive archive of over 2,116 articles which makes the service a
valuable tracking and research tool
- A fast and effective search facility allowing you to identify information
relevant to your needs
- Daily or weekly email alerts which will ensure you know when new
information is added
- An RSS feed facility
Every day, Espicom' s researchers and editors
- Track the companies and research organisations that are shaping the
industry
- Report the latest developments in current and up coming respiratory drugs
- Monitor results from major conferences and meetings
|
 |
